Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 10 | 2022 | 538 | 2.840 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2020 | 50 | 0.790 |
Why?
|
| Cross Infection | 2 | 2022 | 323 | 0.780 |
Why?
|
| Rubinstein-Taybi Syndrome | 1 | 2022 | 16 | 0.780 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2022 | 71 | 0.760 |
Why?
|
| Interleukin-10 | 1 | 2022 | 172 | 0.730 |
Why?
|
| Sepsis | 2 | 2022 | 478 | 0.720 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2021 | 11 | 0.720 |
Why?
|
| Sodium Benzoate | 1 | 2020 | 4 | 0.700 |
Why?
|
| Catheter-Related Infections | 1 | 2022 | 128 | 0.700 |
Why?
|
| Burkitt Lymphoma | 1 | 2022 | 144 | 0.700 |
Why?
|
| STAT3 Transcription Factor | 3 | 2021 | 220 | 0.690 |
Why?
|
| Hyperammonemia | 1 | 2020 | 62 | 0.670 |
Why?
|
| Atovaquone | 1 | 2019 | 8 | 0.670 |
Why?
|
| Phenylbutyrates | 1 | 2020 | 58 | 0.670 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 111 | 0.640 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 107 | 0.640 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 208 | 0.620 |
Why?
|
| Homeodomain Proteins | 1 | 2021 | 543 | 0.570 |
Why?
|
| Brain Diseases | 1 | 2020 | 299 | 0.560 |
Why?
|
| Immunotherapy | 1 | 2021 | 673 | 0.500 |
Why?
|
| Signal Transduction | 2 | 2019 | 4493 | 0.490 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 781 | 0.480 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 1018 | 0.470 |
Why?
|
| Child | 11 | 2022 | 24371 | 0.350 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 2 | 2020 | 20 | 0.330 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2022 | 681 | 0.300 |
Why?
|
| Neoplasms | 1 | 2022 | 2788 | 0.290 |
Why?
|
| Recurrence | 3 | 2022 | 1421 | 0.280 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2022 | 95 | 0.220 |
Why?
|
| Humans | 19 | 2022 | 124693 | 0.210 |
Why?
|
| Haploidy | 1 | 2022 | 19 | 0.200 |
Why?
|
| Chlorhexidine | 1 | 2022 | 45 | 0.200 |
Why?
|
| Blood Platelet Disorders | 1 | 2022 | 13 | 0.190 |
Why?
|
| Prognosis | 2 | 2022 | 4622 | 0.190 |
Why?
|
| CREB-Binding Protein | 1 | 2022 | 64 | 0.190 |
Why?
|
| Fractures, Spontaneous | 1 | 2021 | 18 | 0.190 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 103 | 0.190 |
Why?
|
| STAT5 Transcription Factor | 1 | 2021 | 89 | 0.180 |
Why?
|
| Interleukin-6 | 1 | 2022 | 419 | 0.170 |
Why?
|
| Mediastinal Neoplasms | 1 | 2020 | 42 | 0.170 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2019 | 33 | 0.170 |
Why?
|
| Interleukin-15 | 1 | 2020 | 92 | 0.170 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 87 | 0.160 |
Why?
|
| Bone Marrow Transplantation | 1 | 2022 | 573 | 0.160 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 158 | 0.160 |
Why?
|
| Testicular Neoplasms | 1 | 2020 | 132 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 310 | 0.160 |
Why?
|
| Chromosome Aberrations | 1 | 2022 | 616 | 0.160 |
Why?
|
| Osteomyelitis | 1 | 2021 | 206 | 0.160 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 3335 | 0.150 |
Why?
|
| Patient Satisfaction | 1 | 2022 | 474 | 0.150 |
Why?
|
| Periosteum | 1 | 2019 | 33 | 0.150 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 465 | 0.150 |
Why?
|
| Paresis | 1 | 2018 | 35 | 0.150 |
Why?
|
| Bacteremia | 1 | 2022 | 407 | 0.140 |
Why?
|
| Cell Survival | 1 | 2019 | 806 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 882 | 0.130 |
Why?
|
| Child, Preschool | 5 | 2021 | 14013 | 0.130 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 129 | 0.130 |
Why?
|
| Cytokines | 1 | 2022 | 1290 | 0.130 |
Why?
|
| Infant | 4 | 2021 | 12471 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 184 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1140 | 0.130 |
Why?
|
| Genotype | 1 | 2022 | 2556 | 0.130 |
Why?
|
| Rhodium | 1 | 2015 | 4 | 0.130 |
Why?
|
| Methotrexate | 1 | 2018 | 341 | 0.120 |
Why?
|
| Female | 7 | 2022 | 66548 | 0.120 |
Why?
|
| Naphthalenes | 1 | 2015 | 37 | 0.120 |
Why?
|
| Apoptosis | 2 | 2019 | 1790 | 0.120 |
Why?
|
| Hemophilia B | 1 | 2015 | 7 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1214 | 0.120 |
Why?
|
| Survival Rate | 1 | 2020 | 2045 | 0.120 |
Why?
|
| Adolescent | 5 | 2021 | 19278 | 0.120 |
Why?
|
| Transcriptome | 1 | 2021 | 952 | 0.120 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 420 | 0.110 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 827 | 0.110 |
Why?
|
| Mutation | 3 | 2022 | 5825 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2015 | 261 | 0.110 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 4345 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1486 | 0.100 |
Why?
|
| Mice, Knockout | 1 | 2019 | 3715 | 0.100 |
Why?
|
| Liver Diseases | 1 | 2015 | 366 | 0.090 |
Why?
|
| Adult | 2 | 2022 | 29473 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 1662 | 0.090 |
Why?
|
| Young Adult | 2 | 2021 | 9021 | 0.080 |
Why?
|
| Male | 6 | 2021 | 61257 | 0.070 |
Why?
|
| Mice | 3 | 2020 | 17578 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 2015 | 1038 | 0.070 |
Why?
|
| Animals | 3 | 2020 | 34025 | 0.050 |
Why?
|
| Vidarabine | 1 | 2022 | 80 | 0.050 |
Why?
|
| Cytarabine | 1 | 2022 | 98 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 39 | 0.050 |
Why?
|
| Levofloxacin | 1 | 2022 | 45 | 0.050 |
Why?
|
| Upper Extremity | 1 | 2021 | 54 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2021 | 80 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 65 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2021 | 73 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2021 | 97 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2022 | 119 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 80 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 285 | 0.040 |
Why?
|
| Diarrhea | 1 | 2022 | 317 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2021 | 484 | 0.040 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 183 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 371 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 862 | 0.040 |
Why?
|
| Antidotes | 1 | 2018 | 12 | 0.040 |
Why?
|
| Leucovorin | 1 | 2018 | 49 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 1435 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 1356 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 556 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2019 | 187 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 142 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 717 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 607 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2015 | 93 | 0.030 |
Why?
|
| Catalysis | 1 | 2015 | 126 | 0.030 |
Why?
|
| Factor IX | 1 | 2015 | 15 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 210 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1701 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 574 | 0.030 |
Why?
|
| Leukocytes | 1 | 2015 | 205 | 0.030 |
Why?
|
| Point Mutation | 1 | 2015 | 346 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 1198 | 0.030 |
Why?
|
| Binding Sites | 1 | 2015 | 1295 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 5158 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1688 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 2428 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 1758 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 2285 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 1738 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 2982 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 16323 | 0.010 |
Why?
|